Filing summary
Entity discrepancy: The request identifies Opus Genetics, Inc., but the supplied filing is Rexahn Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended March 31, 2017. This summary reflects the supplied Rexahn filing; verify the intended company and period.
Business context and reporting period
Rexahn was a clinical-stage cancer drug developer with no commercial product revenue. Its pipeline included RX-3117, Supinoxin (RX-5902) and Archexin in Phase II development, plus preclinical programs. The unaudited report covers the three months ended March 31, 2017, with balance-sheet comparisons to December 31, 2016.
Key financial metrics
| Metric | Q1 2017 | Q1 2016 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.26 million | $3.47 million, down 34.8% |
| General and administrative expense | $1.69 million | $1.40 million, up 21.2% |
| Operating loss | $3.95 million | $4.86 million |
| Net loss | $21.61 million | $4.15 million |
| Basic and diluted loss per share | $0.09 | $0.02 |
| Cash used in operations | $4.17 million | $3.55 million |
| Cash and cash equivalents | $10.49 million | $11.58 million at Dec. 31, 2016 |
| Marketable securities | $8.02 million | $8.74 million at Dec. 31, 2016 |
Gross margin is not meaningful because the company reported no revenue. Cash plus marketable securities totaled approximately $18.50 million at quarter-end. Total assets were $19.58 million; total liabilities were $18.45 million, including $16.23 million of warrant liabilities measured at fair value. The filing does not disclose interest-bearing debt. Current assets were $19.47 million and current liabilities were approximately $18.45 million.
Material changes versus prior comparable period
- Net loss increased substantially, chiefly because of a $17.69 million noncash unrealized loss from remeasuring warrants, compared with an $856,000 unrealized gain in Q1 2016. Management attributed the change primarily to the common-stock price rising from $0.14 at year-end to $0.51 at March 31, alongside volatility and the number of warrants outstanding.
- R&D expense fell as manufacturing costs declined to approximately $288,000 from $1.41 million, partly offset by increased clinical costs. G&A expense rose with higher personnel costs and professional fees.
- Financing cash inflow was $2.37 million from warrant exercises, versus $4.58 million of net offering proceeds in Q1 2016. The company issued 7.54 million shares from warrant exercises during the quarter.
Outlook, risks and unusual items
- Management said cash, cash equivalents and marketable securities should fund current activities for at least 12 months from issuance of the financial statements. It also stated that further capital will be needed to continue development; financing may not be available on acceptable terms, and failure to raise capital could require reduced R&D activity.
- Management expected expenses to rise during the remainder of 2017 as clinical enrollment and manufacturing activity increased. It anticipated higher spending on RX-3117 and Supinoxin, broadly flat Archexin expense, and a modest increase in preclinical spending. No revenue or earnings guidance was provided.
- Clinical development, regulatory approval, reliance on third-party research organizations and manufacturers, intellectual property, and future financing are identified risks. The company reported approximately $8.6 million in estimated costs to complete vendor R&D agreements; these agreements may be terminated subject to notice provisions.
- Subsequent events included $2.99 million of additional warrant-exercise proceeds and 8.98 million shares issued after quarter-end. The company also announced a planned 1-for-10 reverse stock split expected to take effect May 5, 2017, and shareholders approved increasing the 2013 stock-plan reserve from 17 million to 34 million shares.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. It reported no material changes to the risk factors in its 2016 Form 10-K.
Important facts for investors to verify
- Confirm that Rexahn’s 2017 Q1 filing, rather than an Opus Genetics filing, is the intended source.
- Review the warrant terms, valuation assumptions and potential dilution; warrant fair value is a large, volatile noncash liability.
- Assess cash runway against planned trial enrollment, manufacturing needs and the stated need for additional capital.
- Check the status and terms of the announced reverse split, subsequent warrant exercises and expanded stock-plan authorization.
- Track clinical-trial progress and spending for RX-3117, Supinoxin and Archexin, including any delays or changes in development plans.